Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18124380 | 0.98 | KDM4E (0.72) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL18124403 | 0.94 | KDM4E (0.65) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL18124374 | 0.89 | — | — | |
| SCHEMBL27980382 | 0.87 | KDM4E (1.00) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL9473718 | 0.84 | KDM4E (0.70) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL18124388 | 0.82 | KDM4E (0.67) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL3535515 | 0.81 | KDM4E (0.79) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL16822348 | 0.81 | KDM4E (0.79) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL11425371 | 0.80 | KDM4E (0.48) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL12857497 | 0.80 | KDM4E (0.63) | KDM4ESMN1; SMN2HTTKMT2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078409-B1 | ACIDIC GAS ABSORBING AGENT, METHOD FOR REMOVING ACIDIC GAS AND APPARATUS FOR REMOVING ACIDIC GAS | TOSHIBA KK (JP) | 2019-01-09 | — | — | EP | disclosed |
| CN-106039931-A | Acidic gas absorbing agent, method for removing acidic gas and apparatus for removing acidic gas | 株式会社东芝 | 2016-10-26 | — | — | CN | disclosed |
| EP-3078409-A1 | ACIDIC GAS ABSORBING AGENT, METHOD FOR REMOVING ACIDIC GAS AND APPARATUS FOR REMOVING ACIDIC GAS | Kabushiki Kaisha Toshiba (JP) | 2016-10-12 | — | — | EP | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1131213-C | Carbostyril derivatives as antithrombotic agents | NISHI MEDICAL RES INST CO LTD (JP) | 2003-12-17 | — | — | CN | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0796248-B1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | WESTERN THERAPEUTICS INST D (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6143763-A | Carbostyril derivatives | D. WESTERN THERAPEUTICS INSTITIUTE (JP) | 2000-11-07 | — | — | US | disclosed |
| CN-1172478-A | Quinolone derivative antithrombotic agent | OTSUKA PHARMA CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0796248-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997012869-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-04-10 | — | — | WO | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | KDM4E 1999/4885SMN1; SMN2 3484/4885HTT 4247/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | KDM4E 1567/4885SMN1; SMN2 3594/4885HTT 4169/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | KDM4E 1999/4885SMN1; SMN2 3484/4885HTT 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.